Results 91 to 100 of about 103,385 (306)

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

Advanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel, Anna Meurer, Badeel Kh. Q. Zaghla, Bilge Atay, Daniel Steiert, Luca V. Hummel, Konstandina Isaakidis, Chuanbing Zang, Michael Korenkov, Marlon Schielin, Schayan Yousefian, Shima Mecklenbräuker, Marieluise Kirchner, Simon Haas, Antonia Busse, Philipp Mertins, Stefan Müller, Matthias Wirth, Martin G. Klatt, Ulrich Keller   +19 more
wiley   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Peripheral T-cell lymphoma: novel backbone [PDF]

Blood, 2018
In this issue of Blood, Amengual et al report the results of a single-institution dose-escalation phase 1 study of pralatrexate plus romidepsin for patients with relapsed/refractory non-Hodgkin lymphoma. This combination resulted in a very high response rate in patients with previously treated peripheral T-cell lymphoma (PTCL ...
openaire   +2 more sources

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms [PDF]

, 2011
Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities,
Agirre, Xabier, Alvarez, Sara, Ammerpohl, Ole, Bibikova, Marina, Brüggemann, Monika, Bug, Stefanie, Calasanz, Maria J., Cruz Cigudosa, Juan, Deckert, Martina, Dreyling, Martin, Du, Ming Q., Dyer, Martin J. S., Dürig, Jan, Fan, Jian-Bing, Gesk, Stefan, Haferlach, Claudia, Hansmann, Martin-Leo, Harder, Lana, Hartmann, Sylvia, Klapper, Wolfram, Küppers, Ralf, Martin-Subero, Jose Ignacio, Montesinos-Rongen, Manuel, Nagel, Inga, Pott, Christiane, Prosper, Felipe, Richter, Julia, Román-Gómez, José, Seifert, Marc, Siebert, Reiner, Stein, Harald, Suela, Javier, Trümper, Lorenz, Vater, Inga, Wickham-Garcia, Eliza   +34 more
core  

Clinicopathological features of extranodal lymphomas: Kuwait experience [PDF]

, 2004
A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and ...
Bamanikar S, D'Amore F, Ducreux M, F. Sinowatz, Freeman C, Gospodarowicz MK, H. Amanguno, H. Baker, Hauke RJ, J.P. Madda, L. Temmim, Longo DL, Neugut AI, Penn I, Shome DK, Stiller CA, Weisenburger DD, Zeeb H   +17 more
core   +1 more source

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

Advanced Science, EarlyView.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang, Weijiao Xu, Lei Zhao, Lin Zhong, Wendan Yu, Shengmin Wang, Lu Sun, Tao Guo, Fengzhou Li, Zhuoshi Li, Lei Fang, Shiqing Wang, Guohui Zhang, Guoqing Xue, Wei Guo, Shilei Zhao, Chundong Gu   +16 more
wiley   +1 more source

Peripheral T-Cell Lymphomas: Therapeutic Approaches

Cancers, 2022
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare neoplasms of mature T cells or natural killer (NK) cell. PTCLs usually have an aggressive course and a poor outcome. In recent years, significant progress has been made in the knowledge of the molecular lymphomagenesis of PTCLs, and through the development of new, more specific ...
openaire   +2 more sources

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. [PDF]

, 1992
Engagement of the CD3/T cell antigen receptor complex on small, resting T cells is insufficient to trigger cell-mediated cytotoxicity or to induce a proliferative response.
Azuma, M, Buck, D, Cayabyab, M, Lanier, LL, Phillips, JH   +4 more
core   +1 more source

Perforated small intestine in a patient with T-cell lymphoma; a rare cause of peritonitis [PDF]

, 2016
The nontraumatic perforations of the small intestine are pathological entities with particular aspects in respect to diagnosis and treatment. These peculiarities derive from the nonspecific clinical expression of the peritonitis syndrome, and from the ...
Banu, Petrisor, Constantin, Vlad D, Nistor, Mihaela F, Popa, Florian   +3 more
core   +3 more sources

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source